By demonstrating that the modulation of this pathway affects the expression of key stemness markers, we propose that targeting Hedgehog signalling could serve as a novel approach to mitigate resistance and improve the efficacy of trastuzumab in HER2-positive breast cancer treatment. Here, ERBB2 is linked to breast carcinoma.